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The factors responsible for the development of unstable
angina pectoris, coronary artery spasm (Prinzmetal's an-
gina) and acute myocardial ischemia or infarction, are not
completely defined. Some patients with extensive and severe
coronary artery stenoses do well with medical therapy, whereas
others with similar or even less impressive coronary artery
stenoses abruptly develop unstable ischemic heart disease .
An improved insight into the mechani sms responsible for
the conversion of chronic to acute coronary artery disease
is essential to prevent acute myocardial infarction and sud-
den cardiac death. In this editorial , we have attempted 1)
to examine the recent developments in our understanding
of alterations in prostaglandin and serotonin production that
may playa role in the development or perpetuation of acute
ischemic heart disease , and 2) to speculate about the mech-
anisms responsible for coronary artery spasm.
Mechanisms Responsible for
Myocardial Ischemia
Most patients with angina pectoris have significant fixed
coronary artery stenoses. Two mechanisms are responsible
for the development of myocardial ischemia: I) increased
myocardial oxygen demand . and 2) decreased myocardial
perfusion and oxygen delivery. In most patient s with stable
angina, physical effort or emotion. with a resultant increase
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in heart rate. blood pressure or contractile state. or any
combination thereof, increases myocardial oxygen demand
without an adequate increase in oxygen delivery through
tightly stenosed coronary arteries . As a result. myocardial
ischemia develops. Occasionally, the patient with stable
angina has a combination of effort and rest angina. In this
circumstance, rest angina is probably caused by a decrease
in myocardial oxygen delivery. perhaps resulting from coro-
nary vasospasm or other mechanisms discussed later.
In contrast to typical stable angina, the acute ischemic
heart disease syndromes (unstable angina. coronary artery
spasm and acute myocardial infarction) are usually caused
by a primary decrease in myocardial oxygen delivery (1-6).
Both unstable angina ;md Prinzmetal's angina are caused
by a primary reduction in myocardial oxygen delivery. but,
in all probability. the mechanisms reponsible for the de-
crease in myocardial blood flow in these two syndromes are
generally different. Acute myocardial infarction may com-
plicate either unstable angina or coronary spasm when myo-
cardial oxygen supply is diminished below critical levels
for a sustained period (7).
Unstable Angina Pectoris
Unstable angina pectoris is defined as angina that in-
creases in frequency. occurring with progressively less ef-
fort . and often at rest. Any factor that results in abrupt or
progressive coronary artery luminal diameter narrowing may
cause diminished myocardial perfusion at low levels of ac-
tivity , or even at rest , with resultant ischemia and unstable
angina. Table 1 lists several possible causes of unstable
angina. In some patient s, the syndrome may result from the
progression of severe , multifocal coronary atherosclerosis .
However, in many patients. other mechanisms are involved
because there is not a good correlation between acute isch-
emic heart disease and the anatomic extent and severity of
atherosclerosis.
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Figure 1. Ratiosof thromboxane 8 2 (Tx82) in the coronary sinus
(CS) and ascending aorta (AO) in the five groups of patients
(n = 60) studied. Each point represents the data from one patient.
Squares identifypatients who receiveda cyclooxygenase inhibitor
within5 days of study, and triangles represent patients with coro-
nary artery spasm. 111 Groups A (valvular and congenital nonisch-
emic heart disease), B (chest painsyndromewithoutischemicheart
disease) and C (ischemic heart disease without chest pain for at
least 96 hours), the patients had thromboxane 8 2 coronary si-
nus/aorta ratios of 3.1 or less. Group D patients (unstable angina
pectoriswithchest pain 24 to 96 hours beforestudy) had a bimodal
distribution: 12 patients had low ratios, whereas 3 had very high
ratios. Group E patients (unstable angina pectoris with chest pain
within 24 hours before study) had ratios that were higher than
those in patients in Groups A, 8 and C (p < 0.05). (Reprinted
from Hirsh PO, et a!. [8) with permission.)
Animal Studies
Thromboxane mechanisms. In the canine heart, a se-
vere proximal coronary artery stenosis with associated endo-
thelial injury causes cyclic coronary blood flow reductions
(Fig . 2) (11,12). Dazoxiben (UK-37-248 , a thromboxane
synthetase inhibitor, Pfizer Pharmaceuticals) (12) or a
thromboxane receptor antagonist (SQ 29,548, Squibb Phar-
maceuticals) (13) abolished or significantly attenuated the
frequency of cyclic flow reductions in approximately 80%
of treated animals, whereas the frequency and magnitude
of cyclic flow reductions were unchanged after the admin-
istration of saline solution. Thromboxane 8 2 concentrations
in the coronary artery and at the coronary stenosis were
increased during cyclic flow reductions and reduced to con-
trol values after administration of dazoxiben (12). In con-
trast, 6-keto-prostaglandin F 1a (the inactive metabolite of
prostacyclin) concentrations were reduced at the site of coro-
Table 1. Potential Causes of Unstable Angina Pectoris
I . Progressive coronary artery narrowing from atherosclerosis .
2. Platelet aggregation at the site of a coronary artery stenosis leading to
increased luminal narrowing due to anatomic obstruction and
dynamic changes in coronary vascular tone. See text for details.
3. Any combination of plaque fissure, hemorrhage or thrombosis with
progressive coronary artery narrowing.
4. Coronary artery spasm .
Previous Evaluations of Alterations in
Prostaglandin Metabolism in Patients
With Unstable Angina
Clinical Studies
In 1979, we (8) tested the hypothesis that unstable angina
is associated with transmyocardial alterations in thrornbox-
ane A2 production. In 60 patients undergoing cardiac cath-
eterization, blood samples were obtained from the coronary
sinus and ascending aorta, and prostaglandins were mea-
sured by radioimmunoassay (8-10) . By history, noninva-
sive evaluation and the results of cardiac catheterization,
the patients were separated into five groups: Group A pa-
tients (n = 6) had congenital and acquired noncoronary
cardiac lesions but were without significant coronary ste-
noses; Group B patients (n = 14) complained of chest pain
but had no significant coronary artery stenoses or provokable
coronary spasm; Group C patients (n = 18) had significant
coronary artery disease and their most recent episode of
chest pain occurred more than 96 hours before study; Group
D patients (n = 15) had chest pain that had occurred 24 to
96 hours before study; and Group E patients (n = 7) had
unstable angina with chest pain within 24 hours of study.
Thromboxane B2 (the inactive metabolite ofthromboxane
A2) concentrations were elevated across the coronary bed
in Group E patients (those with continuing rest angina) (Fig.
I) and values in this group were significantly higher than
those of patients in Groups A, Band C. Group D patients
had a bimodal distribution; 12 patients had a low concen-
tration and 3 had a markedly elevated value . It is not clear
why three patients in Group D had elevated concentrations
of thromboxane B2 • Two possible explanations include I)
persistent increases in cardiac thromboxane B2 concentra-
tion after the relief of unstable angina pectoris, and 2) con-
tinuing unstable angina pectoris not detected clinically or
identified by the patient.
Thus , these data demonstrate a temporal relation between
continuing unstable angina pectoris and increases in trans-
cardiac thromboxane 8 2 concentration . These findings are
consistent with the view that platelet aggregation is an im-
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nary artery constriction, and substantially less 6-keto-pros-
taglandin Flo was synthesized after the in vitro addition of
arachidonic acid as compared with that occurring in the
nonconstricted, noninjured coronary artery (14). Distal
coronary artery 6-keto-prostaglandin Flo levels also in-
creased significantly during cyclic flow reductions, and re-
mained elevated after administration of dazoxiben (12). Sys-
temically administered dazoxiben (2.5 mg/kg body weight,
intravenously) suppressed arachidonic acid-induced throm-
boxane Bz (but not prostaglandin Ez) production by canine
platelets, but dazoxiben (1 /LM) did not significantly affect
prostacyclin synthesis by canine coronary artery rings (12).
Thus, thromboxane and prostacyclin concentrations in-
crease substantially in the distal portion of a severely sten-
osed canine coronary artery. The thromboxane concentra-
tion also increases and the prostacyclin concentration decreases
at the site of the stenosis in association with cyclic flow
reductions. Furthermore, the administration of a thrombox-
ane synthetase inhibitor (dazoxiben) or a thromboxane re-
ceptor antagonist (SQ 29,548) abolishes or markedly atten-
uates cyclic flow reductions, and the thromboxane synthetase
inhibitor reduces the thromboxane concentration in the distal
coronary artery beyond the site of coronary artery constric-
tion.
Serotonin mechanisms. More recently, we have tested
the hypotheses that aggregating platelets at the site of a tight
proximal coronary artery stenosis release serotonin (5-hy-
droxytryptamine) and that serotonin is also an important
factor in initiating or sustaining cyclic flow reductions in
this same experimental model (15,16). Approximately 10
to 20% of animals fail to have their cyclic flow reductions
abolished or markedly attenuated by a thromboxane syn-
thetase inhibitor or receptor antagonist. Ketanserin, a se-
rotonin receptor antagonist, usually abolishes cyclic flow
reductions in this model and works in essentially every
instance in which a thromboxane synthetase inhibitor or
Figure 2. A representative recording from a dog with a severe
coronary arterystenosisand cyclic flow alterations. Note the distal
decline in coronaryartery pressure and phasicand meancoronary
blood flow during cyclic flow variations. Thromboxane synthesis
inhibitors, thromboxane receptor antagonists and a serotonin re-
ceptor antagonist usually abolishor attenuate the cyclic flow vari-
ations. The effect of ketanserin (K) (a serotonin receptor antag-
onist) in abolishing the cyclic flow variations is demonstrated.
Ao = aortic;Cor. = coronary; Dist. = distal;dP/dt = maximal
rate of rise in pressure; LV = left ventricular; Press. = pressure.
(Reprinted from Bush LR, et al. [15] with permission.)
receptor antagonist, or both, has failed (Fig. 2) (15). In
addition, the serotonin concentration increases 18- to 27-
fold at the site of a coronary artery stenosis when cyclic
flow reductions occur. Furthermore, after their abolition
with ketanserin, cyclic flow reductions may be restored by
the intraatrial administration of serotonin (16). Thus, both
thromboxane and serotonin appear to be important in ini-
tiating or sustaining cyclic flow reductions, or both, in this
experimental model. Moreover, if the contribution from
either is eliminated or antagonized, cyclic flow reductions
are usually terminated (17). Platelet aggregation can also
be enhanced by the administration of platelet activating fac-
tor (18) (a product released in various inflammatory reac-
tions), adenosine diphosphate and the activation of alpha-
2-adrenergic receptors (19). However, in the canine model,
alpha-adrenergic antagonists have a relatively weak effect
on platelet aggregation (15).
Influence of Aspirin in Patients
With Unstable Angina
If platelet aggregation and the consequent release of
thromboxane and serotonin are important in the initiation
or sustaining of unstable angina, an intervention that inter-
feres with platelet aggregation and the subsequent release
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of these humoral mediators should reduce morbidity and
mortality in patients with this clinical syndrome. Indeed,
recent clinical studies (20,21) have shown that aspirin, an
inhibitor of cyclooyxygenase, thromboxane synthesis and
platelet aggregation, reduces the risk of subsequent myo-
cardial infarction and death in patients with unstable angina.
Specifically, a multicenter Veterans Administration hospital
study (20) established that I tablet of aspirin (300 mg/day)
reduces mortality and the risk of myocardial infarction in
the weeks after the onset of unstable angina in men. More
recently, a Canadian study (21) demonstrated that the equiv-
alent of 4 aspirin tablets/day reduces mortality and the risk
of subsequent myocardial infarction in the ensuing 2 years
in men and women with unstable angina. These data are
consistent with the hypothesis that platelet aggregation and
subsequent increases in local thromboxane and serotonin
concentrations may playa role in causing acute myocardial
infarction or death, or both, in patients with unstable angina.
They also suggest that the inhibition of the thromboxane
effect is of clinical benefit in patients with unstable angina,
even if the prostacyclin concentration is also reduced (as
occurs with the higher doses of aspirin).
Platelet aggregation and coronary thrombosis. We
have speculated previously that sudden death and acute myo-
cardial infarction (7) may result from progressive platelet
aggregation with concomitant local increases in thrombox-
ane and serotonin concentrations. Such increases within a
stenosed coronary artery contribute to platelet aggregation
and dynamic increases in coronary vascular tone (Fig. 3).
When coronary arteries are occluded or narrowed for a suf-
ficient period of time by these mechanisms, myocardial
necrosis or electrical instability and sudden death may occur
(7). Ambrose et al. (22) showed that the morphologic ap-
pearance of narrowed coronary arteries in patients with un-
stable angina and acute transmural myocardial infarction is
similar, and is characterized by an eccentric stenosis with
a narrow neck presumably reflecting a partially occluding
coronary thrombus at a severe coronary artery stenosis. Thus,
unstable angina and acute myocardial infarction probably
represent a continuum in relation to the process of coronary
artery thrombosis (7,22). Increased local concentrations of
histamine, platelet activating factor or leukotrienes released
from aggregating platelets or infiltrating white cells may
also increase coronary vascular tone, promote platelet ag-
gregation and contribute to the development of unstable
angina or acute myocardial infarction.
Coronary Artery Spasm
We believe that Prinzmetal's angina, the syndrome of
chest pain occurring at rest associated with focal obliteration
(spasm) of the lumen of a large epicardial coronary artery
and transient ST segment deviation (usually elevation) and
Figure 3. A schematic diagram indicating the possible mecha-
nisms by which thromboxane A z (TxAz) and serotonin (5HT) pro-
mote platelet aggregation and decrease coronary blood flow in the
patient with angina. Aggregating platelets (stars) release throm-
boxane Az and serotonin, which cause further platelet aggregation
downstream and dynamic alterations in coronary vascular tone.
See text for details. (Modified with permission from Hirsch PO,
Campbell WB, Willerson JT, Hillis LD. Prostaglandins and isch-
emic heart disease. Am J Med 1981;71:1009-26.)
unstable angina generally have different pathophysiologic
mechanisms. Coronary artery spasm, as it manifests itself
in Prinzmetal's angina, ordinarily responds well to one of
the slow channel calcium blockers with or without nitrates
(23). Patients with Prinzmetal's angina occasionally present
with unstable angina or acute myocardial infarction, but, in
a large number of patients, it has not been possible to dem-
onstrate by coronary arteriography and clinical observations
that coronary spasm is the pathophysiologic event generally
leading to unstable angina or acute myocardial infarction.
Mechanisms. The mechanisms responsible for coronary
artery spasm have not been elucidated. Most patients with
spasm are heavy smokers and smoking itself may cause
coronary vasoconstriction mediated, at least in part, through
alpha-adrenergic mechanisms (24). Studies from our insti-
tution (25) have failed to demonstrate genetic transmission
of coronary artery spasm. Apart from slow channel calcium
blockers and nitrates, no therapeutic intervention has proved
uniformly effective in treating patients with Prinzmetal's
angina (26-30). Histamine and ergonovine have provoked
coronary artery spasm in atherosclerotic swine and canine
models (31,32), and vasopressin has been shown occasion-
ally to provoke coronary spasm in patients (Pitt B, personal
communication, 1986). Morphologic evaluations of coro-
nary arteries that have demonstrated spasm during life are
few in number, but one recent evaluation (33) suggested an
increased number of mast cells in the adventitia, thereby
leading to speculation that humoral mediators released from
infiltrating mast cells, such as histamine, serotonin or pros-
taglandin D2, may be responsible for the development of
coronary artery spasm.





Etiology. Because the provocative influences and effec-
tiveness of selected therapeutic regimens vary among pa-
tients with coronary artery spasm, the etiology of spasm
may also vary from one subject to another. Approximately
three-fourths of patients with coronary vasospasm have sig-
nificant atherosclerotic stenoses. Etiologic possibilities to
explain vasospasm include altered autonomic neural control.
altered contractile function and local release of vasoactive
mediators. There is little direct support for the first two
possibilities. We postulate that the exaggerated local con-
tractile response of coronary artery spasm results from the
release of humoral mediators due to I) focal intimal endo-
thelial damage and the consequent accumulation of platelets
and white cells at the site of endothelial injury, or 2) infil-
tration of white cells and mast cells in the adventitia and
interior portions of the artery as a consequence of injury or
progression of vascular disease, or both. The mechanisms
responsible for endothelial or vascular injury probably vary
among patients. but may be immunologically mediated, the
result of mechanical injury or related to atherosclerosis or
infection.
We postulate that vascular injury may lead to an exag-
gerated coronary vascular contractile response (coronary ar-
tery spasm) when the appropriate concentrations of vasocon-
strictors. including single or combined increases in serotonin.
thromboxane, prostaglandin D2 • histamine, platelet acti-
vating factor. selected leukotrienes and vasopressin, occur
locally. This is especially likely when intrinsic vasodilator
substances (prostacyclin or endothelial-derived relaxing fac-
tor) or intrinsic substances that act to prevent thrombus
development (prostacyclin or tissue plasminogen activating
factor) are diminished or absent because of endothelial in-
jury or when their effect is antagonized by an inhibitor at
the same site (34-36). In these individuals. the slow channel
calcium blockers and nitrates, alone or in combination, are
effective. because they reduce coronary vascular contractile
responses to different stimuli independent of specific mech-
anisms causing coronary artery spasm.
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